Henlius, a global biopharmaceutical company under Fosun Pharma, is dedicated to developing and delivering high-quality, affordable, and innovative biologic medicines. Henlius will be joining the BIO International Convention (#BIO2025) in #Boston, June 16–19, one of the world’s largest gatherings for the biotechnology industry. The event will bring together over 20,000 global industry leaders to explore the future of biotechnology, foster innovation, and forge strategic partnerships. As a key player in oncology, autoimmune, and ophthalmic therapeutics, Henlius continues to expand its global footprint. #biotech #biopharmaceutical
#HenliusinFocus Mark your calendars for June 16-19 in Boston! We're excited to showcase our extensive product portfolio during #BIO2025. Be sure to stop by Booth#1885 to connect with the Henlius team and our SVP & Chief Business Officer, Ping Cao —we're ready to explore new global ties and partnerships! 💡 Perfect opportunity to discover our game-changers: serplulimab (1st anti-PD-1 in 1L SCLC) HLX22 (FDA ODD-designated anti-HER2 mAb) HLX43 (PD-L1 ADC - 2nd in clinical stage globally) Save the date & let's advance oncology innovation together. #Innovation #CancerResearch
